Helius Medical Technologies Inc HSDT

Healthcare Medical Devices

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

NDAQ:HSDT - Post by User

Helius Medical Technologies Inc

Bullboard Posts

Comment by prokofievon Mar 06, 2019 2:41pm

89 Views

Post# 29451216

RE:RE:RE:RE:Oppenheimer: Initiating Coverage With Outperform Rating

Agreed, the analyst is just being careful and likely "sandbagging". Once the FDA hits, here are the revisions:

1) US revenue in 2019 and higher revenue in 2020 and beyond given early start

2) 25% discount to US revenue (given pre-FDA) dissapears

3) 70% gross margin will likely be too low

4) Revisions to Canadian numbers as Helius (1) treats more patients in the two existing clinics and (2) opens a clinic in Toronto later this year.

You are looking at a potential 50% revision (25% from discount & 25% from higher revenue).

Prokofiev

Dvorak12 wrote: It's neither, it's just their assumption. Oppenheimer is genreally very careful in the estimates used in their model. This leaves room for upward revision.

miningfundi wrote:
"Our estimates currently don't assume FDA approval in 2019." Is this reasonable or an error?